John Reed
Showing 1–2 of 2 transcripts.
- Milken Institute1h 1m
Biotech: Bull Market or Bubble?
Luke Timmerman, Alex Denner, Bob Hugin, Annalisa Jenkins, John Reed
Panelists from major pharmaceutical firms and investment firms analyzed the biotech sector's transition from a 2012–2015 valuation bubble to a value-driven correction that prioritizes clinical utility over speculative hype. Industry leaders emphasized that while technological convergence in genomics and personalized medicine drives innovation, the sector faces critical challenges in pricing models, R&D efficiency, and patient trial enrollment that threaten long-term profitability. Consensus among the executives suggests that future success depends on collaborative regulatory frameworks, demonstrable patient outcomes, and new manufacturing efficiencies to justify the billions required for drug development.
- Milken Institute1h 3m
2014 London Summit - Collaborating to Fund Bioscience
Margaret Anne Craig, Steve Ford, David Loew, Mark Treherne, John Reed, Margaret Anderson
Industry leaders and UK government officials convened to address the critical friction of clinical trial attrition, highlighting exponential biotech growth in European hubs alongside the urgent need for new biomarkers to de-risk neurodegeneration research. Major pharmaceutical players like Roche and Sanofi are engaging in pre-competitive collaborations to pool data and reduce sample sizes, while academic institutions face pressure to shift from publishing-centric models toward translational commercialization. Simultaneously, patient advocacy groups and policymakers are advocating for consolidated funding strategies and digital tools to align European charitable efforts with US-scale initiatives and accelerate the development of disease-modifying therapies.